Previous 10 | Next 10 |
2024-05-01 07:32:52 ET More on Repligen Repligen misses top-line and bottom-line estimates; initiates FY24 outlook Seeking Alpha’s Quant Rating on Repligen Historical earnings data for Repligen Read the full article on Seeking Alpha For further...
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-year Increased Filtration (non-COVID) revenue by 12% year-over-year Achieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Rep...
2024-04-30 11:52:33 ET More on Repligen Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript Repligen misses top-line and bottom-line estimates; initiates FY24 outlook Repligen Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Repligen ...
2024-04-25 17:01:08 ET Summary Danaher Corporation stock has surged by 16% since our "Strong Buy" rating in June 2023, outperforming the S&P 500. The bioprocessing industry is facing near-term challenges, but long-term growth prospects remain strong. Danaher's Q1 FY24 resu...
2024-04-24 09:10:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. Our portfolio outperformed the Russell Midcap® Growth Index in Q1 due to balance...
Repligen Corporation (NASDAQ: RGEN) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 9.58% on the day to $172.57. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biologic...
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
2024-04-23 06:58:24 ET More on Danaher Danaher: All In On Life Sciences, And Market Update Danaher Corporation (DHR) TD Cowen 44th Annual Health Care Conference (Transcript) Danaher: Better Positioned For The Future Danaher Non-GAAP EPS of $1.92 beats by $0.2...
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2024 financial results on Wednesday, May 1, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-04-10 12:49:59 ET Summary Thermo Fisher Scientific, Danaher Corporation, and Agilent Technologies are leading companies in the life science tools industry. Despite a long history of success with those firms, I believe long-term investors should diversify into growth opportuni...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...